Cargando…
Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities
In this study, we measured the serum concentration of TIMP-2 in patients with systemic sclerosis (SSc) and explored its possible correlation with cardiac and pulmonary lesions. We studied 42 patients with SSc, with duration equal to or more than 2 years. CT chest, ECG, echocardiography, and serum TI...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1775032/ https://www.ncbi.nlm.nih.gov/pubmed/17392585 http://dx.doi.org/10.1155/MI/2006/38458 |
_version_ | 1782131730237358080 |
---|---|
author | Shahin, Amira Elsawaf, Amani Ramadan, Shahira Shaker, Olfat Amin, Mona Taha, Mohamed |
author_facet | Shahin, Amira Elsawaf, Amani Ramadan, Shahira Shaker, Olfat Amin, Mona Taha, Mohamed |
author_sort | Shahin, Amira |
collection | PubMed |
description | In this study, we measured the serum concentration of TIMP-2 in patients with systemic sclerosis (SSc) and explored its possible correlation with cardiac and pulmonary lesions. We studied 42 patients with SSc, with duration equal to or more than 2 years. CT chest, ECG, echocardiography, and serum TIMP-2 concentration measurement using ELISA technique were performed in all patients and in 25 normal controls. The mean serum levels of TIMP-2 in patients was higher than in controls (P = .005). The mean CT score of dSSc patients with elevated TIMP-2 levels was significantly higher than dSSc patients with normal levels (P = .013). Four patients out of five with elevated TIMP-2 levels showed diastolic dysfunction (80%), compared to 2 out of 15 lSSc patients with normal levels (13.3%), with P = .014. Our research, though involving a small group of patients, points to the probable role of TIMP-2 in the development of pulmonary lesions in dSSc patients and cardiac lesions in lSSc patients with duration equal to or more than 2 years. |
format | Text |
id | pubmed-1775032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-17750322007-02-20 Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities Shahin, Amira Elsawaf, Amani Ramadan, Shahira Shaker, Olfat Amin, Mona Taha, Mohamed Mediators Inflamm Research Communication In this study, we measured the serum concentration of TIMP-2 in patients with systemic sclerosis (SSc) and explored its possible correlation with cardiac and pulmonary lesions. We studied 42 patients with SSc, with duration equal to or more than 2 years. CT chest, ECG, echocardiography, and serum TIMP-2 concentration measurement using ELISA technique were performed in all patients and in 25 normal controls. The mean serum levels of TIMP-2 in patients was higher than in controls (P = .005). The mean CT score of dSSc patients with elevated TIMP-2 levels was significantly higher than dSSc patients with normal levels (P = .013). Four patients out of five with elevated TIMP-2 levels showed diastolic dysfunction (80%), compared to 2 out of 15 lSSc patients with normal levels (13.3%), with P = .014. Our research, though involving a small group of patients, points to the probable role of TIMP-2 in the development of pulmonary lesions in dSSc patients and cardiac lesions in lSSc patients with duration equal to or more than 2 years. Hindawi Publishing Corporation 2006 2006-12-20 /pmc/articles/PMC1775032/ /pubmed/17392585 http://dx.doi.org/10.1155/MI/2006/38458 Text en Copyright © 2006 Amira Shahin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Communication Shahin, Amira Elsawaf, Amani Ramadan, Shahira Shaker, Olfat Amin, Mona Taha, Mohamed Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities |
title | Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in
Patients With Systemic Sclerosis With Duration More Than 2
Years: Correlation With Cardiac and Pulmonary Abnormalities |
title_full | Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in
Patients With Systemic Sclerosis With Duration More Than 2
Years: Correlation With Cardiac and Pulmonary Abnormalities |
title_fullStr | Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in
Patients With Systemic Sclerosis With Duration More Than 2
Years: Correlation With Cardiac and Pulmonary Abnormalities |
title_full_unstemmed | Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in
Patients With Systemic Sclerosis With Duration More Than 2
Years: Correlation With Cardiac and Pulmonary Abnormalities |
title_short | Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in
Patients With Systemic Sclerosis With Duration More Than 2
Years: Correlation With Cardiac and Pulmonary Abnormalities |
title_sort | serum levels of tissue inhibitors of metalloproteinase 2 in
patients with systemic sclerosis with duration more than 2
years: correlation with cardiac and pulmonary abnormalities |
topic | Research Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1775032/ https://www.ncbi.nlm.nih.gov/pubmed/17392585 http://dx.doi.org/10.1155/MI/2006/38458 |
work_keys_str_mv | AT shahinamira serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities AT elsawafamani serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities AT ramadanshahira serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities AT shakerolfat serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities AT aminmona serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities AT tahamohamed serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities |